NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $76.39 -1.65 (-2.11%) As of 05/9/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$76.30▼$79.5550-Day Range$69.80▼$88.8252-Week Range$66.66▼$105.47Volume11.44 million shsAverage Volume9.07 million shsMarket Capitalization$4.85 billionAssets Under Management$4.81 billionDividend Yield0.18%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.57%0.52%0.53%Other Expenses0.00%0.30%0.48%0.56%0.52%Total Expense0.35%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.65%-0.54%Net Expense0.35%0.61%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesInvestors Purchase High Volume of SPDR S&P Biotech ETF Put Options (NYSEARCA:XBI)May 8 at 1:41 AM | americanbankingnews.comOptimism is Back for Biotech Stocks. This Time, It Could Last.May 5, 2025 | msn.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 10, 2025 | Brownstone Research (Ad)SPDR S&P Biotech ETF Experiences Big InflowApril 16, 2025 | nasdaq.comFriday's ETF Movers: XBI, COPXMarch 23, 2025 | nasdaq.comInvest In A New Biotech Bull Market With XBI And IBBMarch 2, 2025 | seekingalpha.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 on January 1st, 2025. Since then, XBI shares have decreased by 15.2% and is now trading at $76.39. View the best growth stocks for 2025 here. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional investors of SPDR S&P Biotech ETF include Goldman Sachs Group Inc. (21.29%), Demars Financial Group LLC (4.94%), Bessemer Group Inc. (2.25%) and Migdal Insurance & Financial Holdings Ltd. (1.65%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings149 Fund Statistics Assets Under Management$4.81 billion Average Daily Volume$13.76 million Discount/Premium0.05% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume84,639 Put Options54,747 Call Options29,892 Short Interest66,410,000 shs Miscellaneous Outstanding Shares63,530,000Beta1.00 Creation Unit50,000 Creation Fee$250.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report Top 10 XBI HoldingsNatera (NASDAQ:NTRA)Holding Weight: 2.82%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 2.71%Insmed (NASDAQ:INSM)Holding Weight: 2.70%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.66%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.55%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.55%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.52%Exact Sciences (NASDAQ:EXAS)Holding Weight: 2.47%Amgen (NASDAQ:AMGN)Holding Weight: 2.44%Incyte (NASDAQ:INCY)Holding Weight: 2.36%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.